PRESS RELEASE

PledPharma prepares for listing on the Nasdaq Stockholm main market during 2019

Stockholm, December 5, 2018. The Board of PledPharma AB (publ) has decided to initiate a process to enable listing of the company’s share on Nasdaq Stockholm’s main market in 2019. The PledPharma share has been traded on Nasdaq Stockholm First North since 2011. A listing on the main market is a natural step in the company’s development and its global ambition according to the Board.

PledPharma has applied IFRS accounting since 2014. The pharmaceutical development is well advanced with a global Phase III program for the drug candidate PledOx®, initiated in autumn 2018. PledOx® is being developed to prevent nerve damage caused by chemotherapy treatment in colorectal cancer patients. At the same time, the company is preparing for continued clinical development with the drug candidate Aladote® - a new treatment to treat liver failure caused by paracetamol (acetaminophen) poisoning.

"We see a listing on Nasdaq Stockholm’s main market as a natural step that reflects the maturity of our business, also from a capital markets perspective, which can thus contribute to increased interest from a broader investor base, in Sweden and globally," says Nicklas Westerholm, CEO, PledPharma AB.

For further information, please contact:

Nicklas Westerholm, CEO
Phone +46 (0)73 354 20 62
nicklas.westerholm@pledpharma.se

Yilmaz Mahshid, CFO
Phone +46 (0)72 231 68 00
yilmaz.mahshid@pledpharma.se

About PledPharma

PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company’s most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and serves as the basis for the initiated global phase III program. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. A proof of principle study has been successfully completed and will serve as the basis for the continued development. PledPharma (STO: PLED) is
listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see http://www.pledpharma.se/

This information is information that PledPharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on December 5, 2018.